Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05584631 · ClinicalTrials.gov registry record · Phase 1
IVIG vs SCIG in CIDP
A Phase 1 study of Chronic Inflammatory Demyelinating Polyneuropathy and CIDP, sponsored by Rutgers, The State University of New Jersey.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT05584631: Recruiting Phase 1 study of Chronic Inflammatory Demyelinating Polyneuropathy and CIDP, sponsored by Rutgers, The State University of New Jersey.
NCT05584631 is a Phase 1 study of Chronic Inflammatory Demyelinating Polyneuropathy and CIDP that is actively recruiting participants, run by Rutgers, The State University of New Jersey. The registered enrollment target is 20 participants, below the 159-participant average among 11 other Chronic Inflammatory Demyelinating Polyneuropathy trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05584631, a Phase 1 study of Chronic Inflammatory Demyelinating Polyneuropathy and CIDP, is actively recruiting participants, sponsored by Rutgers, The State University of New Jersey.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
Current dosing practices for immunoglobulin G (IgG) may be inadequate in extreme body weight. The current study will evaluate the influence of body composition on intravenous and subcutaneous administration of immunoglobulin G in patients.
Primary Outcome
Calculation of drug half-life based on data obtained from serum samples
Conditions Studied
Interventions
- DRUG Intravenous immune globulin G
- DRUG Subcutaneous immune globulin G
Study Locations (1)
New Jersey
- Rutgers, The State University of New Jersey Clinical Research Center - New Brunswick
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2022-09-11 |
| Est. Completion | 2026-12-01 |
| Phase | Phase 1 |
What NCT05584631 shows while recruiting
NCT05584631 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 159-participant average among 11 other Chronic Inflammatory Demyelinating Polyneuropathy trials with a reported enrollment target (87% lower).
The record links to 3 conditions, with Chronic Inflammatory Demyelinating Polyneuropathy appearing as the primary indexed condition, and to 2 interventions - of which Intravenous immune globulin G is the first listed.
NCT05584631 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT05584631 about?
NCT05584631 is a clinical study titled "IVIG vs SCIG in CIDP". Current dosing practices for immunoglobulin G (IgG) may be inadequate in extreme body weight. The current study will evaluate the influence of body composition on intravenous and subcutaneous administration of immunoglobulin G in patients.
What is the current status of trial NCT05584631?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2022-09-11. Estimated completion is 2026-12-01.
What conditions does trial NCT05584631 study?
This clinical trial studies the following conditions: Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, Immunoglobulin Deficiency.
What interventions are being tested in trial NCT05584631?
The interventions under investigation include: Intravenous immune globulin G (DRUG), Subcutaneous immune globulin G (DRUG).
Who is sponsoring clinical trial NCT05584631?
This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05584631 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Inflammatory Demyelinating Polyneuropathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05584631's enrollment target sits among peer trials
20 11th of 11 higher than 1 of 11 other Chronic Inflammatory Demyelinating Polyneuropathy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Inflammatory Demyelinating Polyneuropathy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)
RECRUITING · Phase 3
-
A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP
RECRUITING · Phase 3
-
Safety, Tolerability, and Efficacy of NVG-2089 in Participants With CIDP
RECRUITING · Phase 2
-
A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP
RECRUITING · Phase 3
-
IMVT-1402 in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI